Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors

NCT01017640 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

NIH

Sponsor class

Conditions

Solid Neoplasm

Interventions

OTHER: Laboratory Biomarker Analysis
DRUG: Mitomycin
DRUG: Veliparib

Sponsor

National Cancer Institute (NCI)